Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

30.58 -0.03 (-0.10%)
Streaming Delayed Price Updated: 1:37 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pacira Pharm Inc

< Previous 1 2 3 Next >
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. 
Via Investor's Business Daily
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Expert Ratings For Pacira BioSciences
Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
Via Investor's Business Daily
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript
PCRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition
Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value... 
Via Benzinga
Why Pacira Biosciences Stock Sank Today
A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug. 
Via The Motley Fool
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Pacira BioSciences, inc (PCRX) Q2 2021 Earnings Call Transcript
PCRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Outlook For Pacira BioSciences
Pacira BioSciences (NASDAQ:PCRX) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021
Upgrades Tudor Pickering upgraded the previous rating for Precision Drilling Corp (NYSE: 
Via Benzinga
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries
Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal... 
Via Benzinga
Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important
Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego,... 
Via Benzinga
Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript
PCRX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BioVie (NASDAQ:BIVI) shares rose 11.62% to $24.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 27.3K shares,... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.